期刊文献+

非小细胞肺癌中神经内分泌分化和多药耐药性的关系研究

Relationship Between Neuroendocrine Differentiation and Multidrug Resistance in Non-small Cell Lung Cancer
暂未订购
导出
摘要 目的:探讨非小细胞肺癌(NSCLC)中神经内分泌(NE)分化与多药耐药(MDR)的相关性。方法:采用链霉亲和素过氧化酶连接(SP)免疫组化法检测113例NSCLC中神经元特异性烯醇化酶(NSE)、突触素(SYN)和嗜铬素A(CgA)的表达,采用原位分子杂交对同一病例中多药耐药基因(MDR1)和多药耐药相关蛋白(MRP)基因mRNA的表达进行检测,并对相关数据进行统计学处理。结果:①NSCLC中NSE、SYN、CgA的阳性率分别为53.1%,26.6%和6.2%。至少有2种NE标记物表达者有24例(21.2%),其表达与肿瘤的分化程度有关(P<0.05);②MDR1和MRPmRNA在NSCLC组织中的阳性表达率分别为51.3%,80.5%,二者表达与肿瘤组织类型、分化程度、淋巴结转移、TNM分期等无关,二者在NSCLC中的表达存在明显相关(P<0.01);③2种MDR相关基因mRNA在具有NE分化的NSCLC中的表达均较不伴NE分化者为低(P<0.05)。结论:NE分化可能与NSCLC多药耐药性的产生有密切关系。 Objective: To investigate the correlation between neuroendocrine (NE)differentiation and multidrug resistance (MDR) in (non-small cell lung cancer, NSCLC). Methods: The expression of NSE,SYN and CgA were measured by immunohistochemistry. In situ hybridization was used to detect MDR1 and MRP gene. The results were checked with x^2 test. Results. ① The positive rates of the NE markers were 53.1%, 26.6% and 6.2% for NSE, SYN and CgArespectively, and 21.2% for at least two markers positively expressed. The expression of at least two markers was associated with the degree of differentiation (P〈0.05). ②Fifty-eight cases (51.3%) were MDR1 mRNA-positive and nighty-one cases (80.5 %) were MRP mRNA-positive respectively. The expression of MDR1 mRNA and MRP mRNA was not related to histological subtypes, cell differentiation, TNM stages and lymphatic metastasis. There was a significant correlation between expression of MDR1 mRNA and MRP mRNA in NSCLC (P〈0.01). ③ The expression of the two MDR associated genes in the positive group for at least two markers was significantly lower than that in the negative one (P〈0.05). Conclusion: There may be a close relationship between NE differentiation and MDR in NSCLC.
出处 《武汉大学学报(医学版)》 CAS 2006年第2期232-234,共3页 Medical Journal of Wuhan University
基金 湖北省自然科学基金(编号:2002AB145) 湖北省科技攻关计划项目(编号:2002AA304B13)
关键词 肺肿瘤 神经内分泌 多药耐药 免疫组织化学 原位分子杂交 Lung Neoplasms Neuroendocrine Multdrug Resistance Immunohistochemistry In Situ Hybridization
  • 相关文献

参考文献8

  • 1Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein 1 in non-small-cell lung cancer: prognostic implications[J]. J Cancer Res Clin Oncol, 2005, 131(6) :355.
  • 2彭忠民,罗静,王潍博,王晓航,陈景寒,兰守敏.耐药相关基因表达对Ⅲ期非小细胞肺癌新辅助化疗的临床预测价值探讨[J].癌症,2004,23(8):963-967. 被引量:7
  • 3Gao Z, Gao Z, Field JZ, et al. Co-transfection of MDR1 and MRP antisense RNAs abolishes the drug resistance in multidrug-resistance human lung cancer cells[J]. Anticancer research, 1998, 18 (4C): 3073.
  • 4Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of 87 cases[J]. J Thorac Cardiovasc Surg 2002, 124(2):285.
  • 5Bessho T, Yokochi K, Sakurai T. Combined large cell neuroendocrine carcinoma[J]. Jpn J Thorac Cardiovasc Surg, 2004, 52(9): 426.
  • 6Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy[J]. Histopathology,2005, 46(2): 195.
  • 7Carnaghi C, Rimassa L, Garassino I, et al. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer[J]. Ann Oncol, 2001, 12 (Suppl 2) :119.
  • 8Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage Ⅰ non-small cell lung carcinoma[J]. Cancer, 2003, 97 (10):2 487.

二级参考文献12

  • 1Volm M,Koomagi R,Mattern J,et al. Protein expression profiles indicative for drug resistance of non-small cell lung cancer [J]. Br J Cancer,2002,87(3):251- 257.
  • 2Yeh JJ,Hsu WH,Wang JJ,et al. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with p-glycoprotein expression [J].Respiration,2003,70(1):32- 35.
  • 3Kawai H,Kiura K,Tabata M,et al. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy [J]. Lung Cancer,2002,35(3):305- 314.
  • 4Rosell R,Gomez CJ,Camps C,et al. Preresectional chemotherapy in stage Ⅲ A non-small-cell lung cancer:a 7-year assessment of a randomized controlled trial [J]. Lung Cancer,1999,26(1):7- 14.
  • 5Izquierdo MA,van der Zee AG,Vermorken JB,et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma [J]. J Natl Cancer Inst, 1995,87(16):1230- 1237.
  • 6Jiao X,Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer:a new paradigm in thoracic oncology [J]. Ann Thorac Surg. 2002,74(1):278- 284.
  • 7Elias AD,Skarin AT,Leong T,et al. Neoadjuvant therapy for surgically staged Ⅲ A N2 non-small cell lung cancer (NSCLC) [J]. Lung Cancer, 1997,17(1):147- 161.
  • 8Betticher DC,Hsu Schmitz SF,Totsch M,et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage Ⅲ A pN2 non-small-cell lung cancer: a multicenter phase Ⅱ trial [J]. J Clin Oncol,2003,21(9):1752- 1759.
  • 9Voltolini L,Luzzi L,Ghiribelli C,et al. Results of induction chemotherapy followed by surgical resection in patients with stage Ⅲ A (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy [J]. Eur J Cardiothorac Surg,2001,20(6):1106- 1112.
  • 10Trussardi A,Poitevin G,Gorisse MC,et al. Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells [J].Int J Oncol,1998,13(3):543- 548.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部